Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control lotion Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

NCT03341910
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1%, DFD-03 Vehicle Lotion 0%, Tazorac Vehicle Cream 0%
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 10, 2026, 5:24 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Results available

Effects of Massage Therapy to Induce Sleep in Preterm Infants

NCT01354028
View directory record Official record
Conditions
Premature Birth of Newborn
Interventions
Massage therapy
Other
Lead sponsor
University of Arkansas
Other
Eligibility
3 Days to 20 Weeks
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2013 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 10, 2026, 5:24 PM EDT
Terminated Phase 3 Interventional

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

NCT02811783
View directory record Official record
Conditions
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
Interventions
Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test

NCT02750475
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Sport Lotion (BAY987516), Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

NCT00656786
View directory record Official record
Conditions
EGFR Inhibitor-associated Rash
Interventions
Menadione Topical Lotion
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Vallejo, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin

NCT04253704
View directory record Official record
Conditions
Xerosis Cutis
Interventions
IDL lotion, Control lotion
Combination Product
Lead sponsor
Shyla Cantor
Industry
Eligibility
35 Years to 57 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Blauvelt, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Commercial "Sleep Lotion" on Salivary Melatonin Levels and Sleep Quality in Undergraduates

NCT06053385
View directory record Official record
Conditions
Sleep
Interventions
Melatonin sleep lotion, Placebo control lotion
Other
Lead sponsor
University of Redlands
Other
Eligibility
18 Years to 24 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699
View directory record Official record
Conditions
Pediculosis
Interventions
Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional

The Effects of Topical Calcium Glycerophosphate on Surgical Wound Healing and Residual Scarring

NCT01264588
View directory record Official record
Conditions
Wound Healing, Scarring
Interventions
Topical calcium glycerophosphate lotion
Other
Lead sponsor
AkPharma Inc.
Industry
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE

NCT02142959
View directory record Official record
Conditions
Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%, Omaveloxolone Lotion 3%, Vehicle Lotion, 3D conformal radiation therapy
Drug · Radiation
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
27
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Photoallergy Test

NCT02750449
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sun screening Sport Lotion, (BAY987516), Untreated skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old

NCT02831478
View directory record Official record
Conditions
Sunscreening Agent
Interventions
BAY987517, Sunscreen Lotion (RB# T78-190B)
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Years to 9 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional

The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea

NCT03392558
View directory record Official record
Conditions
Rosacea
Interventions
Burt's Bees Skin Care Regimen, Control Regimen
Other
Lead sponsor
Burt's Bees Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Acceptability and Feasibility of a Bedtime Routine for Neonates

NCT06318637
View directory record Official record
Conditions
Newborn
Interventions
Baby Wash/Shampoo, Daily Activities, Body Lotion
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
2 Weeks and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

NCT00244439
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG, Ovide (malathion) lotion 0.05%, Permethrin 1%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
Scottsdale, Arizona • Miami, Florida • St. Petersburg, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2013 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 2 Interventional

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

NCT00089180
View directory record Official record
Conditions
Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions
liposomal T4N5 lotion, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice

NCT03337490
View directory record Official record
Conditions
Head Lice
Interventions
Ivermectin 0.5% Topical Application Lotion, Ivermectin 0.5% Topical Application Lotion [SKLICE], Placebo 0% Lotion
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
6 Months to 18 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
6
States / cities
Dinuba, California • Miami, Florida • Plantation, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Supervised Outdoor-Use Test For Sunscreen Products in Adults

NCT02877511
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987517, Sunscreen Lotion (Y65-110)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 10, 2026, 5:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18349-Human Photoallergy Test

NCT02823496
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Lotion , BAY 987521, Untreated skin
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Sep 10, 2026, 5:24 PM EDT